Drug Profile


Alternative Names: Anagastra; B-8610-23; BY-1023; Controloc; DZ-2352A; Eupantol; Inipomp; Pangest; Pantecta; Pantoloc; Pantop; Pantopan; Pantozol; Peptazol; Protium; Protonix; Rifun; SKF 96022; Somac; Tecta; Tecta Control; Ulcotenal; ZacPac; Zurcal

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Nycomed
  • Developer Takeda Pharmaceuticals International GmbH
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Antiulcers; Gastric antisecretories; Small molecules
  • Mechanism of Action Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Duodenal ulcer; Erosive oesophagitis; Gastric ulcer; Gastritis; Gastro-oesophageal reflux; Heartburn; Helicobacter infections; Peptic ulcer; Zollinger-Ellison syndrome
  • Preclinical Pancreatitis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 12 Dec 2013 Launched prior to December 2013 for Gastro-oesophageal reflux in Brazil, Mexico and the Ukraine (PO)
  • 12 Dec 2013 Final efficacy data from the phase III PAMES trial in erosive Gastro-oesophageal reflux disease released by Takeda Pharmaceuticals International
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top